We use key performance indicator (KPI) data to measure how the NHS screening programmes are performing.
We offer screening for sickle cell and thalassaemia (SCT) to all pregnant women. We also offer to screen the baby’s biological father if the mother is found to be a carrier of or have a sickle cell or thalassaemia condition.
The NHS Fetal Anomaly Screening Programme (FASP) offers screening to pregnant women so they can find out how likely it is that their baby has Down’s (Trisomy 21 or T21), Edwards’ (T18) or Patau’s (T13) syndromes or one of a …
We published a blog in November about non-invasive prenatal testing (NIPT).
Our 3 antenatal screening programmes have joined forces with the national Screening Quality Assurance Service (SQAS) team to hold 8 regional workshops during 2017.
The National Antenatal Infection Screening Monitoring (NAISM) team in Public Health England’s National Infection Service (NIS) has published the 2015 annual summary report on antenatal screening for infectious diseases.
Are you involved in antenatal sickle cell and thalassaemia (SCT) screening? Do you counsel women and couples at risk of having a baby with a significant haemoglobin disorder? Are you aware of all the resources available to support your counselling?
We have published the annual data report for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme covering 1 April 2015 to 31 March 2016.
Over the past few months, the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme has consulted widely with colleagues from a range of services, including midwifery, specialist nurses and clinicians, screening laboratories, and patient organisations to help us revise and …
In this blog article, antenatal and newborn screening coordinator Louise Frost explains how the creation of an antenatal booking centre (ABC) improved early access and continuity of care for women at Princess Royal University Hospital (PRUH) in south east London.